IMM gets SPA for trypanosomiasis Phase III

Immtech (IMM) received an SPA from FDA for an African Phase III trial of DB289 to treat trypanosomiasis. The open-label trial will enroll about 250 patients and will compare oral DB289 with pentamidin...